Abstracts Archive - Page 2331 of 2425 - ACR Meeting Abstracts

Abstract Number: 1365 • 2012 ACR/ARHP Annual Meeting
Double-Blind, Placebo-Controlled, 28-Week Trial of Efficacy and Safety of Infliximab Plus Naproxen Vs Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early, Active Axial Spondyloarthritis Trial, Part I
Joachim Sieper¹, Jan Lenaerts², Jürgen Wollenhaupt³, Vadim Mazurov⁴, L. Myasoutova⁵, Sung-Hwan Park⁶, Yeong W. Song⁷, Ruji Yao⁸, Denesh Chitkara⁸ and Nathan Vastesaeger⁹, ¹Charité, University Medicine Berlin, Berlin, Germany, ²Reuma-instituut, Hasselt, Belgium, ³Schön-Klinik, Hamburg, Germany, ⁴St. Petersburg Medical Academy, St. Petersburg, Russia, ⁵Kazan State Medical University, Kazan, Russia, ⁶Catholic University of Korea, Seoul, South Korea, ⁷Seoul National University, Seoul, South Korea, ⁸Merck Sharp and Dohme, Kenilworth, NJ, ⁹Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Efficacy of anti–tumor necrosis factor (TNF) therapy in patients with axial spondyloarthritis (SpA) has been tested only in patients who are refractory to NSAIDs.…
Abstract Number: 1366 • 2012 ACR/ARHP Annual Meeting
Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo – Controlled Study
Chunde Bao¹, Feng Huang², Muhammad Asim Khan³, Kaiyin Fei⁴, Zhong Wu⁴ and Elizabeth C. Hsia⁴, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Dept of Rheumatology, Chinese PLA General Hospital, Beijing, China, ³Medicine/ Rheumatology, Case Western Reserve University Hospital, Cleveland, OH, ⁴Janssen Research & Development, LLC., Spring House, PA
Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo-Controlled StudyBackground/Purpose: This…
Abstract Number: 1367 • 2012 ACR/ARHP Annual Meeting
Clinical Features and Treatment Results of Japanese Patients with SAPHO (Synovitis-Acne-Pustulosis-Hyperostosis-Osteitis) Syndrome
Hiroki Yabe¹, Takashi Kuroiwa¹, Aya Nonaka¹, Tomomi Tsutsumi¹, Tadashi Sakurai¹, Masato Moriguchi¹, Hisaji Oshima², Kensuke Ochi³ and Chihiro Terai¹, ¹Division of Rheumatology, Jichi Medical University Saitama Medeical Center, Saitama City, Japan, ²Connective Tissue Diseases, Tokyo Medical Ctr, Tokyo, Japan, ³Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: SAPHO syndrome is a disorder characterized by pustular skin lesions and osteoarticular lesions, which was proposed by Chamot et al. in 1987. Clinical studies…
Abstract Number: 1368 • 2012 ACR/ARHP Annual Meeting
Psoriatic Arthritis in South Asians- Comparison with Caucasians of European Descent
Vinod Chandran¹, Arane Thavaneswaran² and Dafna D. Gladman³, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The prevalence of psoriatic arthritis (PsA) varies substantially world-wideand is highest among Caucasians of European descent. Studies from India suggest that patients with PsA…
Abstract Number: 1369 • 2012 ACR/ARHP Annual Meeting
Severe Joint Damage in Psoriatic Arthritis: Mutilans and Ankylosis
Amir Haddad¹, Arane Thavaneswaran¹, Dafna D. Gladman² and Vinod Chandran³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patients with Psoriatic arthritis (PsA) who develop severe joint damage have severe functional disability and increased mortality risk. The most severe form of PsA…
Abstract Number: 1370 • 2012 ACR/ARHP Annual Meeting
Clinical and Ultrasonographic Features of Nail Disease in Psoriasis and Psoriatic Arthritis
Amir Haddad¹, Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The purpose of this study was to investigate the association between clinical and unltrasonographic features of psoriatic nail disease and to identify specific nail…
Abstract Number: 1371 • 2012 ACR/ARHP Annual Meeting
Predictors of Erosion-Free Psoriatic Arthritis
Zahi Touma¹, Arane Thavaneswaran², Vinod Chandran³ and D. D. Gladman⁴, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: A number of patients with psoriatic arthritis (PsA) remain erosion-free despite years of disease. We aimed to determine the prevalence, characteristics and predictors of…
Abstract Number: 1372 • 2012 ACR/ARHP Annual Meeting
Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Désirée van der Heijde¹, Jürgen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum Berlin, Berlin, Germany, ⁴UCB Pharma, Braine, Belgium, ⁵UCSD School of Medicine, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA). AS significantly affects patients' (pts) work productivity.1 The impact of the…
Abstract Number: 1373 • 2012 ACR/ARHP Annual Meeting
Influence of Early Onset On the Clinical Characteristics and Prognosis of Ankylosing Spondylitis
Maria Aparicio¹, Jesús Rodríguez-Moreno¹, Paula Estrada¹, Irene Martín-Esteve², Laura López-Vives¹, Vicenç Torrente³, Jordi Anton⁴, Joan Miquel Nolla⁵ and Xavier Juanola⁶, ¹Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ²Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ³Rheumatology, Hospital Sant Joan de Déu, Barcelona, Spain, ⁴Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, ⁵Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: To determine the influence of early onset (≤ 16 years) on the clinical characteristics and prognosis of ankylosing spondylitis (AS). Methods: We revised patients…
Abstract Number: 1374 • 2012 ACR/ARHP Annual Meeting
Value of C-Reactive Protein Level At Diagnosis of Psoriatic Arthritis in Predicting the Future Need for Treatment with Tumor Necrosis Factor-á Inhibitors
Yair Molad¹ and Shachaf Ofer-Shiber², ¹Rheumatology Unit, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petach-Tikva, Israel, ²Internal Medicine H, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel
Background/Purpose: To determine the value of acute-phase reactant levels at diagnosis of psoriatic arthritis in predicting the risk of failure of conventional treatment with disease-modifying…
Abstract Number: 1375 • 2012 ACR/ARHP Annual Meeting
Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors
Emily McDonough¹, Arane Thavaneswaran², Adele Carty³, Sutharshini Shanmugarajah², Renise Ayearst⁴, Lihi Eder⁴, Vinod Chandran⁵, Cheryl Rosen⁶ and Dafna D. Gladman⁷, ¹Medicine, University of Toronto, Ontario, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁶Division of Dermatology, University of Toronto, Toronto western Hospital, Toronto, ON, Canada, ⁷Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis and has the potential to cause severe joint damage. Research into the prevalence of…
Abstract Number: 1336 • 2012 ACR/ARHP Annual Meeting
Changes in the Levels of Anti-Cyclic Citrullinated Protein Antibody and Immunoglobulins in Rheumatoid Arthritis Patients After Administration of Tocilizumab
Masao Sato¹, Masao Takemura², Ryuki Shinohe³, Tsuneo Watanabe² and Katsuji Shimizu³, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Informative Clinical Medicine, Gifu University, Gifu, Japan, ³Orthopaedic Surgery, Gifu University, Gifu, Japan
Background/Purpose: The recently established scoring system of American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) early arthritis diagnosis criteria have assigned scores of 0, 1,…
Abstract Number: 1337 • 2012 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Pharmacokinetic Profile and Its Relationship to Changes in Pharmacodynamic Markers in Patients with Rheumatoid Arthritis
Pavel Belomestnov¹, Jennifer Hamilton², A. Thomas DiCioccio¹, Martine Jasson³ and Allen R. Radin⁴, ¹Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Clinical Development, Sanofi-Aventis, Paris, France, ⁴Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY
Background/Purpose: Sarilumab, a fully human monoclonal antibody targeting interleukin-6 receptor alpha (IL-6Rα), is being evaluated for the treatment of rheumatoid arthritis (RA) based on the…
Abstract Number: 1338 • 2012 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Factor Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by which Anti-Tumor Necrosis Factor Might Reduce Inflammation
M.M. Herenius¹, A.S.F. Oliveira¹, C.A. Wijbrandts¹, D. Gerlag¹, Paul P. Tak² and Maria C. Lebre³, ¹Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Chemerin is a specific chemoattractant for macrophages and dendritic cells (DC). In addition, it can rapidly stimulate macrophage adhesion to extracellular matrix proteins and…
Abstract Number: 1339 • 2012 ACR/ARHP Annual Meeting
A Pilot Study Investigating the Tolerability and Pharmacodynamic Effect of Single Intravenous/Subcutaneous Doses of Olokizumab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Rheumatoid Arthritis
Roy Fleischmann¹, Alan J. Kivitz², Frank Wagner³, Jeffrey A. Feinstein⁴, Uwe Fuhr⁵, Jürgen Rech⁶, Jagdev Sidhu⁷, Philip L. Hill⁸, Ruth Oliver⁸ and Kosmas Kretsos⁹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Altoona Center for Clinical Research, Duncansville, PA, ³Charité Research Org GmbH, Berlin, Germany, ⁴San Antonio, TX, ⁵Hospital of the University of Cologne (AöR), Köln, Germany, ⁶Medizinische Klinik 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁷CSL Limited, Parkville, Australia, ⁸UCB Celltech, Slough, United Kingdom, ⁹UCB, Slough, United Kingdom
Background/Purpose: Olokizumab is a novel IL-6 inhibitor that selectively blocks the final assembly of the IL-6 signaling complex (gp80+gp130+IL-6). We report the safety, PK, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].